Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer
AuthorsWatt, Matthew J
Clark, Ashlee K
Selth, Luke A
Haynes, Vanessa R
Porter, Laura H
Whitby, Sarah T
Schittenhelm, Ralf B
Anderson, Kimberley E
Wijayaratne, Poornima R
Montgomery, Magdalene K
Risbridger, Gail P
Nomura, Daniel K
Taylor, Renea A
AffiliationDepartment of Physiology, University of Melbourne, Melbourne, VIC 3010, Australia
MetadataShow full item record
AbstractMetabolism alterations are hallmarks of cancer, but the involvement of lipid metabolism in disease progression is unclear. We investigated the role of lipid metabolism in prostate cancer using tissue from patients with prostate cancer and patient-derived xenograft mouse models. We showed that fatty acid uptake was increased in human prostate cancer and that these fatty acids were directed toward biomass production. These changes were mediated, at least partly, by the fatty acid transporter CD36, which was associated with aggressive disease. Deleting Cd36 in the prostate of cancer-susceptible Pten(-/-) mice reduced fatty acid uptake and the abundance of oncogenic signaling lipids and slowed cancer progression. Moreover, CD36 antibody therapy reduced cancer severity in patient-derived xenografts. We further demonstrated cross-talk between fatty acid uptake and de novo lipogenesis and found that dual targeting of these pathways more potently inhibited proliferation of human cancer-derived organoids compared to the single treatments. These findings identify a critical role for CD36-mediated fatty acid uptake in prostate cancer and suggest that targeting fatty acid uptake might be an effective strategy for treating prostate cancer.
CitationWatt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, et al. Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. Sci Transl Med. 2019 Feb 6;11(478).
JournalScience Translational Medicine
- Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.
- Authors: Wang S, Wu J, Suburu J, Gu Z, Cai J, Axanova LS, Cramer SD, Thomas MJ, Perry DL, Edwards IJ, Mucci LA, Sinnott JA, Loda MF, Sui G, Berquin IM, Chen YQ
- Issue date: 2012 Feb
- Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.
- Authors: Lu TL, Huang YF, You LR, Chao NC, Su FY, Chang JL, Chen CM
- Issue date: 2013 Mar
- Early intervention exercise training does not delay prostate cancer progression in Pten<sup>-/-</sup> mice.
- Authors: Taylor RA, Farrelly SG, Clark AK, Watt MJ
- Issue date: 2020 Aug
- MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells.
- Authors: Li X, Chen YT, Josson S, Mukhopadhyay NK, Kim J, Freeman MR, Huang WC
- Issue date: 2013
- Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.
- Authors: Bjerke GA, Yang CS, Frierson HF, Paschal BM, Wotton D
- Issue date: 2014 Jul 10